Enveric Biosciences (ENVB) Competitors $1.17 -0.06 (-4.88%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.20 +0.03 (+2.14%) As of 04/17/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENVB vs. SNOA, LIXT, SPRC, IMCC, VRAX, ARAV, JAGX, ELAB, ARTL, and NBYShould you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Sonoma Pharmaceuticals (SNOA), Lixte Biotechnology (LIXT), SciSparc (SPRC), IM Cannabis (IMCC), Virax Biolabs Group (VRAX), Aravive (ARAV), Jaguar Health (JAGX), Elevai Labs (ELAB), Artelo Biosciences (ARTL), and NovaBay Pharmaceuticals (NBY). These companies are all part of the "pharmaceutical products" industry. Enveric Biosciences vs. Sonoma Pharmaceuticals Lixte Biotechnology SciSparc IM Cannabis Virax Biolabs Group Aravive Jaguar Health Elevai Labs Artelo Biosciences NovaBay Pharmaceuticals Sonoma Pharmaceuticals (NASDAQ:SNOA) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability. Is SNOA or ENVB more profitable? Enveric Biosciences has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -26.82%. Sonoma Pharmaceuticals' return on equity of -68.98% beat Enveric Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-26.82% -68.98% -26.39% Enveric Biosciences N/A -221.54%-164.32% Do analysts prefer SNOA or ENVB? Enveric Biosciences has a consensus target price of $10.00, suggesting a potential upside of 754.70%. Given Enveric Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Enveric Biosciences is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enveric Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, SNOA or ENVB? Sonoma Pharmaceuticals has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Does the media favor SNOA or ENVB? In the previous week, Sonoma Pharmaceuticals and Sonoma Pharmaceuticals both had 1 articles in the media. Sonoma Pharmaceuticals' average media sentiment score of 1.00 equaled Enveric Biosciences'average media sentiment score. Company Overall Sentiment Sonoma Pharmaceuticals Positive Enveric Biosciences Positive Does the MarketBeat Community believe in SNOA or ENVB? Sonoma Pharmaceuticals received 210 more outperform votes than Enveric Biosciences when rated by MarketBeat users. Likewise, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 60.00% of users gave Enveric Biosciences an outperform vote. CompanyUnderperformOutperformSonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Enveric BiosciencesOutperform Votes660.00% Underperform Votes440.00% Do institutionals and insiders believe in SNOA or ENVB? 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 3.9% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 3.2% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, SNOA or ENVB? Sonoma Pharmaceuticals has higher revenue and earnings than Enveric Biosciences. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$13.97M0.27-$4.84M-$4.02-0.57Enveric BiosciencesN/AN/A-$17.29M-$38.38-0.03 SummarySonoma Pharmaceuticals beats Enveric Biosciences on 9 of the 15 factors compared between the two stocks. Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENVB vs. The Competition Export to ExcelMetricEnveric BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$793,000.00$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.036.8921.8017.78Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.115.916.443.97Net Income-$17.29M$142.72M$3.21B$247.65M7 Day Performance-6.40%4.38%2.85%1.80%1 Month Performance-30.77%-12.76%-8.64%-6.98%1 Year Performance-91.68%-9.69%11.38%1.34% Enveric Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENVBEnveric Biosciences2.7656 of 5 stars$1.17-4.9%$10.00+754.7%-91.2%$793,000.00N/A-0.0320Short Interest ↓Positive NewsGap DownSNOASonoma Pharmaceuticals1.208 of 5 stars$1.91-5.4%N/A+1,268.2%$3.09M$13.97M-0.48180Short Interest ↓Positive NewsLIXTLixte Biotechnology0.9554 of 5 stars$1.15-5.8%N/A-64.0%$3.07MN/A-0.664Short Interest ↓Positive NewsSPRCSciSparc0.7119 of 5 stars$0.28+3.0%N/A-78.6%$3.02M$1.75M0.004Short Interest ↓Gap DownIMCCIM Cannabis0.3513 of 5 stars$1.34-2.2%N/A-55.8%$2.99M$54.03M-0.39340Short Interest ↑VRAXVirax Biolabs Group2.6914 of 5 stars$0.92-5.7%$3.00+226.1%+44.4%$2.97M$84,872.000.005Gap DownARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading VolumeJAGXJaguar Health0.0654 of 5 stars$4.79+9.6%N/A-97.8%$2.95M$11.69M0.0050Short Interest ↑Gap DownELABElevai Labs0.4692 of 5 stars$4.09-4.4%N/A-99.7%$2.89M$2.45M-0.0718Short Interest ↑Gap DownARTLArtelo Biosciences2.2259 of 5 stars$0.88-4.1%$5.50+525.0%-27.5%$2.89MN/A-0.315Negative NewsGap DownNBYNovaBay Pharmaceuticals2.957 of 5 stars$0.49-4.8%$0.85+72.8%-78.9%$2.86M$13.84M-0.0130Analyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies SNOA Alternatives LIXT Alternatives SPRC Alternatives IMCC Alternatives VRAX Alternatives ARAV Alternatives JAGX Alternatives ELAB Alternatives ARTL Alternatives NBY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENVB) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENVB Stock Free ENVB Stock Alerts